PDF(Pubmed)
Abstract：
Acute myeloid leukemia (AML) remains a challenging hematologic malignancy. The presence of TP53 mutations in AML poses a therapeutic challenge, considering that standard treatments face significant setbacks in achieving meaningful responses. There is a pressing need for the development of innovative treatment modalities to overcome resistance to conventional treatments attributable to the unique biology of TP53-mutated (TP53mut) AML. This review underscores the role of TP53 mutations in AML, examines the current landscape of treatment options, and highlights novel therapeutic approaches, including targeted therapies, combination regimens, and emerging immunotherapies, as well as agents being explored in preclinical studies according to their potential to address the unique hurdles posed by TP53mut AML.
摘要：
急性髓细胞性白血病（AML）仍然是一种具有挑战性的血液系统恶性肿瘤。AML中TP53突变的存在提出了治疗挑战，考虑到标准治疗在实现有意义的反应方面面临重大挫折。迫切需要开发创新的治疗方式以克服对归因于TP53突变的(TP53mut)AML的独特生物学的常规治疗的抗性。这篇综述强调了TP53突变在AML中的作用。检查当前的治疗方案，并强调了新的治疗方法，包括靶向治疗,组合方案，和新兴的免疫疗法，以及根据其解决TP53mutAML所带来的独特障碍的潜力在临床前研究中正在探索的药物。
